Elevated exhalation of hydrogen peroxide in patients with non-small cell lung cancer is not affected by chemotherapy

Figures & data

Table 1. Characteristic of 30 patients with non-small cell lung cancer (NSCLC) and 15 apparently healthy controls.

Parameter^a	Healthy controls	NSCLC patients
Mean age [years]	61.3 ± 9.3	62.8 ± 8.5
Sex (M/F)	13/2	25/5
Body mass index [kg/m^2]	24.2 ± 1.6	24.0 ± 3.3
Current smokers/non-smokers	30/0	15/0
Daily cigarette consumption	23 ± 5	19 ± 6
Cumulative cigarette consumption [pack-years]	38 ± 7	43 ± 10
White blood cells [×10^3/µL]	7.24 ± 1.48	9.85 ± 3.80^b
Neutrophils [×10^3/µL]	4.14 ± 1.27	7.14 ± 3.59^b
Erythrocytes [×10^6/µL]	4.33 ± 0.38	4.44 ± 0.56
Hemoglobin [g/dL]	13.4 ± 1.2	13.4 ± 1.5
Hematocrit [%]	40.7 ± 3.8	40.4 ± 4.3
Platelets [×10^3/µL]	268 ± 65	317 ± 146
ECOG performance status [(0–5)/number of patients]	N/A	0/13 1/17

^aData are shown as the ratio or mean ± SD where appropriate. N/A – not applicable, ECOG – Eastern Cooperative Oncology Group score.

^bP < 0.05 vs. healthy controls.

Figure 1. EBC H₂O₂ concentrations in NSCLC patients before and after the first, second, and the fourth cycle of CHT in comparison to the control group. *P < 0.05 vs. control group.

Table 2. EBC H₂O₂ concentrations in patients with PR, SD, and PD during CHT.

Subgroup of NSCLC patients^a	Cycle of CHT	H2O2 concentrations in exhaled breath condensate [µmol/L]
		Before the cycle mean ± SD	After the cycle mean ± SD
PR patients (n = 16)	1st	0.48 ± 0.17	0.55 ± 0.19
	2nd	0.52 ± 0.20	0.58 ± 0.21
	4th	0.42 ± 0.11	0.52 ± 0.18^b
SD patients (n = 4)	1st	0.50 ± 0.12	0.42 ± 0.12
	2nd	0.48 ± 0.16	0.50 ± 0.19
	4th	0.44 ± 0.07	0.46 ± 0.13
PD patients (n = 10)	1st	0.51 ± 0.11	0.54 ± 0.17
	2nd	0.54 ± 0.14	0.52 ± 0.13
	4th	0.52 ± 0.09	0.54 ± 0.23

^aNumber of subjects in each subgroup resulted from NSCLC patients classification according to the RECIST criteria after completion of four CHT cycles.

^bP < 0.05 vs. H₂O₂ level before the cycle.

Table 3. Serum concentrations of TBARS in 30 NSCLC patients during CHT.

Cycle of CHT	Serum TBARS [µmol/L]
	Before the cycle	After the cycle
1st	4.02 ± 3.54	4.63 ± 3.30
2nd	3.61 ± 3.24	4.95 ± 3.98
4th	3.07 ± 3.33	4.15 ± 3.40

No significant differences were noted between corresponding values before and after CHT cycle.